NCT04781634View on ClinicalTrials.gov

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 7, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

July 1, 2027

Conditions
B-ALL
Interventions
BIOLOGICAL

CD19 and CD22 targeted prime CAR-T cells

A single infusion of CD19 and CD22 prime CAR-T cells will be administered intravenously

Trial Locations (1)

Unknown

RECRUITING

920th Hospital of Joint Logistics Support Force, Kunming

All Listed Sponsors
lead

Chongqing Precision Biotech Co., Ltd

INDUSTRY